Alzheimer's disease (AD) is a neurodegenerative disease that is characterized by the loss of
synapses and neurons in the brain, and the accumulation of amyloid plaques. Aβ oligomers …

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease of
growing interest given that there is cognitive damage and symptom onset acceleration …

While plaques comprised of fibrillar Aβ aggregates are hallmarks of Alzheimer's disease,
soluble Aβ oligomers present higher neurotoxicity. Thus, one therapeutic approach is to …

In Alzheimer's disease (AD), Amyloid-beta (Aβ) oligomers are considered an appealing
therapeutic-and diagnostic target. However, to date, the molecular mechanisms associated …

Amyloid β (Aβ) oligomers play a key role in the progression of Alzheimer's disease (AD).
Multiple forms of Aβ assemblies have been identified by in vitro and in vivo analyses; …

Alzheimer's disease (AD), one of the progressive neurodegenerative disorders, is
characterized by clinical features such as memory loss, acquired skill loss, apraxia, and …

Synaptic function is essential for cognition and loss of synapses is observed in
neurodegenerative tauopathies including Progressive Supranuclear Palsy (PSP) …

Alzheimer's disease (AD) is tightly correlated with synapse loss in vulnerable brain regions.
It is assumed that specific molecular entities such as Aβ and tau cause synapse loss in AD …

Amyloid β-protein (Aβ) plays an initiating role in Alzheimer's disease (AD), but only a small
number of groups have studied Aβ extracted from human brain. Most prior studies have …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects the
patient's quality of life. The current regime of drugs only halts the symptoms of the disease …